本帖最后由 老马 于 2012-1-13 21:20 编辑 ! p2 T4 r; A2 a/ w! l- @ I
. d5 n. ~# b6 }% `
爱必妥和阿瓦斯丁的比较
9 A% O6 H n* z0 w
1 V5 x' W+ a& ?" lhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/% J; F6 L' h U+ |/ \$ ^" g3 C
" u: G. ^! m& q- U- M% k
, w! b$ P# O7 X* M9 K3 Z( m5 p4 \
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/2 } ?0 N4 X6 _; r
==================================================
9 [8 {+ a7 C8 A0 c* r8 ]4 X- G! EOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
- G$ ?# j% D% z2 j1 DPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point., u" x& P9 O9 F, D& ]1 M
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
; E3 S$ K* m2 { s( a
|